Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Ziemiecka, Anna
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
S
Siemionow M
,
Biegański G
,
Niezgoda A
,
Wachowiak J
,
Czarnota J
,
Siemionow K
,
Ziemiecka A
,
Sikorska MH
,
Bożyk K
,
Heydemann A
.
Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
Stem Cell Rev Rep. 2023.
PubMed
Google Scholar
A
Niezgoda A
,
Biegański G
,
Wachowiak J
,
Czarnota J
,
Siemionow K
,
Heydemann A
,
Ziemiecka A
,
Sikorska MH
,
Bożyk K
,
Siemionow M
.
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
Arch Immunol Ther Exp (Warsz). 2023;71(1):24.
PubMed
Google Scholar